Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual ...
Occult CNV Size in Wet-AMD is Predictive of Success of OHR-102 Combination Therapy Results Drive Patient Selection and Design for Phase 3 Program NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research …